Ultragenyx Pharmaceutical (RARE) Asset Utilization Ratio (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Asset Utilization Ratio for 10 consecutive years, with 0.47 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 12.95% year-over-year to 0.47; the TTM figure through Mar 2026 stood at 0.47 (up 12.95% YoY), while the FY2025 annual figure was 0.44, up 18.56% from the prior year.
• Asset Utilization Ratio declined to 0.47 in Q1 2026 per RARE's latest filing, from 0.49 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.5 in Q3 2025 and bottomed at 0.23 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.34 across 5 years, with a median of 0.32 in 2023.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio dropped 2.61% — and 2025, when it soared 52.47%.
• Ultragenyx Pharmaceutical's Asset Utilization Ratio stood at 0.23 in 2022, then surged by 38.48% to 0.32 in 2023, then rose by 15.79% to 0.37 in 2024, then jumped by 34.2% to 0.49 in 2025, then slipped by 4.16% to 0.47 in 2026.
• Business Quant data shows RARE's Asset Utilization Ratio at 0.47 in Q1 2026, 0.49 in Q4 2025, and 0.5 in Q3 2025.